Claims
- 1. A method for detecting binding of an antibody that specifically reacts with an Fkhsf polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2, said method comprising the steps of:(a) contacting a biological sample with an antibody, or an antibody fragment thereof, that specifically binds to an Fkhsf polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2, under conditions that allow binding of said antibody or antibody fragment to the Fkhsf polypeptide; and (b) detecting binding of the antibody, or antibody fragment thereof.
- 2. A method for detecting binding of an antibody that specifically reacts with a mutant Fkhsf polypeptide, said mutant Fkhsf polypeptide being encoded by a polynucleotide comprising the sequence set forth in SEQ ID NO: 1 wherein the sequence has an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, said method comprising the steps of:(a) contacting a biological sample with an antibody, or an antibody fragment thereof, that specifically binds to a mutant Fkhsf polypeptide encoded by a polynucleotide comprising the sequence set forth in SEQ ID NO:1 wherein the sequence has an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, under conditions that allow binding of the antibody or antibody fragment to the mutant Fkhsf polypeptide, and (b) detecting binding of the antibody, or antibody fragment thereof.
- 3. The method of either claim 1 or claim 2 wherein said antibody is selected from the group consisting of:(a) polyclonal antibody, (b) a murine monoclonal antibody, (c) a humanized antibody derived from (b), and (d) a human monoclonal antibody.
- 4. The method of either claim 1 or claim 2, wherein said antibody fragment is selected from the group consisting of F(ab′)2, F(ab)2, Fab′, Fab, Fv, sFv, and minimal recognition unit.
- 5. A method for detecting binding of an antibody that specifically reacts with an Fkhsf polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2, said method comprising the steps of:(a) contacting a biological sample with an antibody, or an antibody fragment thereof, that specifically binds to an Fkhsf polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2, wherein the antibody or the antibody fragment thereof comprises a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold, under conditions that allow binding of said antibody or antibody fragment to the Fkhsf polypeptide; and (b) detecting binding of the antibody, or antibody fragment thereof.
- 6. A method for detecting binding of an antibody that specifically reacts with a mutant Fkhsf polypeptide, said mutant Fkhsf polypeptide being encoded by a polynucleotide comprising the sequence set forth in SEQ ID NO:1 wherein the sequence has an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO: 12, said method comprising the steps of:(a) contacting a biological sample with an antibody, or an antibody fragment thereof, that specifically binds to a mutant Fkhsf polypeptide encoded by a polynucleotide comprising the sequence set forth in SEQ ID NO:1 wherein the sequence has an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, wherein the antibody or the antibody fragment thereof comprises a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold, under conditions that allow binding of the antibody or antibody fragment to the mutant Fkhsf polypeptide, and (b) detecting binding of the antibody, or antibody fragment thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
The application is a divisional of pending U.S. patent application Ser. No. 09/372,668 filed Aug. 11, 1999 now U.S. Pat. No. 6,414,129, which application claims priority from U.S. Provisional Patent Application No. 60/096,195 filed Aug. 11, 1998, which applications are incorporated herein by reference in their entirety.
Non-Patent Literature Citations (5)
Entry |
Colman et al., Research in Immunology 145(1):33-36, 1994.* |
Abaza et al., Journal of Protein Chemistry 11(5):433-444, 1992.* |
Lederman et al., Molecular Immunology 28:1171-1181, 1991.* |
Li et al in PNAS 77:3211-3214, 1980.* |
Ngo et al., Protein Folding problem and Tertiary Structure prediction, 1994, Merz et al., (ed), Birkhauser, Boston, MA, pp. 433 and 492-495. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/096195 |
Aug 1998 |
US |